Zimmer Biomet (NYSE:ZBH) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Zimmer Biomet (NYSE:ZBH) posted its quarterly earnings data on Wednesday. The medical equipment provider reported $2.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.99 by $0.02, Briefing.com reports. Zimmer Biomet had a return on equity of 12.70% and a net margin of 12.93%. The business had revenue of $1.94 billion during the quarter, compared to analyst estimates of $1.94 billion. During the same period last year, the company earned $1.82 EPS. The company’s revenue for the quarter was up 3.9% on a year-over-year basis. Zimmer Biomet updated its FY24 guidance to $8.00-8.15 EPS and its FY 2024 guidance to 8.000-8.150 EPS.

Zimmer Biomet Price Performance

Shares of NYSE:ZBH traded down $0.62 during trading hours on Friday, hitting $108.08. 1,161,469 shares of the company’s stock traded hands, compared to its average volume of 1,502,015. Zimmer Biomet has a 52 week low of $102.00 and a 52 week high of $133.90. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.80 and a current ratio of 1.66. The company’s fifty day simple moving average is $108.98 and its two-hundred day simple moving average is $118.61. The company has a market cap of $22.24 billion, a price-to-earnings ratio of 23.39, a price-to-earnings-growth ratio of 1.97 and a beta of 1.01.

Zimmer Biomet Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, July 31st. Stockholders of record on Wednesday, June 26th were given a dividend of $0.24 per share. The ex-dividend date was Wednesday, June 26th. This represents a $0.96 annualized dividend and a dividend yield of 0.89%. Zimmer Biomet’s dividend payout ratio (DPR) is 20.78%.

Wall Street Analysts Forecast Growth

A number of research firms have commented on ZBH. Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a research note on Thursday. Evercore ISI decreased their target price on shares of Zimmer Biomet from $115.00 to $113.00 and set an “in-line” rating for the company in a report on Thursday. Morgan Stanley reduced their price objective on shares of Zimmer Biomet from $130.00 to $120.00 and set an “equal weight” rating for the company in a research note on Monday, July 15th. Truist Financial lowered their target price on shares of Zimmer Biomet from $130.00 to $117.00 and set a “hold” rating on the stock in a report on Tuesday, July 16th. Finally, The Goldman Sachs Group started coverage on shares of Zimmer Biomet in a research note on Thursday, May 30th. They set a “neutral” rating and a $129.00 price target for the company. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $127.67.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.